View in EDS

Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.

Saved in:
Bibliographic Details
Title: Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.
Authors: Sweet K; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. kendra.sweet@moffitt.org., Komrokji R; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Padron E; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Cubitt CL; Department of Translational Research, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Turner JG; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Zhou J; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., List AF; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Sallman DA; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Dawson JL; Department of Experimental Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Sullivan DM; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Chavez J; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Shah BD; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Lancet JE; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Jan 01; Vol. 26 (1), pp. 54-60. Date of Electronic Publication: 2019 Oct 21.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-19-2169